Univariate and multivariate analyses of treatment-related mortality
. | . | Univariate analysis . | . | Multivariate analysis . | . | ||
|---|---|---|---|---|---|---|---|
| Variable . | No. . | Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | ||
| Age at transplantation | .035 | — | |||||
| Younger than 40 y | 158 | 1.00 | — | ||||
| 40 y or older | 75 | 1.82 (1.04-3.17) | — | ||||
| Clinical subtype | .349 | — | |||||
| Indolent | 38 | 1.00 | — | ||||
| Lymphoblastic | 84 | 1.47 (0.66-3.32) | — | ||||
| Clinical subtype | .103 | — | |||||
| Indolent | 38 | 1.00 | — | ||||
| Aggressive | 111 | 1.91 (0.88-4.16) | — | ||||
| Aggressive lymphoma | .045 | — | |||||
| PTCL | 22 | 1.00 | — | ||||
| Non-PTCL | 89 | 2.85 (1.02-7.94) | — | ||||
| Response to chemotherapy | < .001 | < .001 | |||||
| Sensitive | 128 | 1.00 | 1.00 | ||||
| Resistant | 105 | 3.41 (1.97-5.88) | 2.95 (1.66-5.25) | ||||
| Prior autograft | < .001 | < .001 | |||||
| No | 193 | 1.00 | 1.00 | ||||
| Yes | 40 | 4.74 (2.23-10.07) | 4.09 (1.85-9.04) | ||||
| Prior radiotherapy | .010 | — | |||||
| No | 152 | 1.00 | — | ||||
| Yes | 81 | 2.05 (1.18-3.55) | — | ||||
| Years of transplantation | .225 | — | |||||
| 1996-2001 | 187 | 1.00 | — | ||||
| 1990-1995 | 46 | 1.49 (0.78-2.86) | — | ||||
| Donor | .295 | — | |||||
| HLA-matched | 197 | 1.00 | — | ||||
| HLA-mismatched | 36 | 1.46 (0.72-2.98) | — | ||||
| HLA-matched donor | .437 | — | |||||
| Related | 154 | 1.00 | — | ||||
| Unrelated | 43 | 1.24 (0.72-2.15) | — | ||||
| Source of stem cells* | .544 | — | |||||
| BM | 159 | 1.00 | — | ||||
| PBSCs | 70 | 1.09 (0.82-1.46) | — | ||||
| Conditioning regimen | .144 | — | |||||
| TBI-containing | 193 | 1.00 | — | ||||
| Others | 40 | 1.67 (0.84-3.30) | — | ||||
| GVHD prophylaxis† | .169 | — | |||||
| Cyclosporin + methotrexate | 204 | 1.00 | — | ||||
| Tacrolimus + methotrexate | 22 | 1.86 (0.77-4.51) | — | ||||
| Acute GVHD | .537 | — | |||||
| No | 78 | 1.00 | — | ||||
| Yes | 155 | 1.19 (0.69-2.06) | — | ||||
| Chronic GVHD | < .001 | .029 | |||||
| No | 79 | 1.00 | 1.00 | ||||
| Yes | 154 | 2.76 (1.53-4.98) | 2.02 (1.07-3.77) | ||||
. | . | Univariate analysis . | . | Multivariate analysis . | . | ||
|---|---|---|---|---|---|---|---|
| Variable . | No. . | Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | ||
| Age at transplantation | .035 | — | |||||
| Younger than 40 y | 158 | 1.00 | — | ||||
| 40 y or older | 75 | 1.82 (1.04-3.17) | — | ||||
| Clinical subtype | .349 | — | |||||
| Indolent | 38 | 1.00 | — | ||||
| Lymphoblastic | 84 | 1.47 (0.66-3.32) | — | ||||
| Clinical subtype | .103 | — | |||||
| Indolent | 38 | 1.00 | — | ||||
| Aggressive | 111 | 1.91 (0.88-4.16) | — | ||||
| Aggressive lymphoma | .045 | — | |||||
| PTCL | 22 | 1.00 | — | ||||
| Non-PTCL | 89 | 2.85 (1.02-7.94) | — | ||||
| Response to chemotherapy | < .001 | < .001 | |||||
| Sensitive | 128 | 1.00 | 1.00 | ||||
| Resistant | 105 | 3.41 (1.97-5.88) | 2.95 (1.66-5.25) | ||||
| Prior autograft | < .001 | < .001 | |||||
| No | 193 | 1.00 | 1.00 | ||||
| Yes | 40 | 4.74 (2.23-10.07) | 4.09 (1.85-9.04) | ||||
| Prior radiotherapy | .010 | — | |||||
| No | 152 | 1.00 | — | ||||
| Yes | 81 | 2.05 (1.18-3.55) | — | ||||
| Years of transplantation | .225 | — | |||||
| 1996-2001 | 187 | 1.00 | — | ||||
| 1990-1995 | 46 | 1.49 (0.78-2.86) | — | ||||
| Donor | .295 | — | |||||
| HLA-matched | 197 | 1.00 | — | ||||
| HLA-mismatched | 36 | 1.46 (0.72-2.98) | — | ||||
| HLA-matched donor | .437 | — | |||||
| Related | 154 | 1.00 | — | ||||
| Unrelated | 43 | 1.24 (0.72-2.15) | — | ||||
| Source of stem cells* | .544 | — | |||||
| BM | 159 | 1.00 | — | ||||
| PBSCs | 70 | 1.09 (0.82-1.46) | — | ||||
| Conditioning regimen | .144 | — | |||||
| TBI-containing | 193 | 1.00 | — | ||||
| Others | 40 | 1.67 (0.84-3.30) | — | ||||
| GVHD prophylaxis† | .169 | — | |||||
| Cyclosporin + methotrexate | 204 | 1.00 | — | ||||
| Tacrolimus + methotrexate | 22 | 1.86 (0.77-4.51) | — | ||||
| Acute GVHD | .537 | — | |||||
| No | 78 | 1.00 | — | ||||
| Yes | 155 | 1.19 (0.69-2.06) | — | ||||
| Chronic GVHD | < .001 | .029 | |||||
| No | 79 | 1.00 | 1.00 | ||||
| Yes | 154 | 2.76 (1.53-4.98) | 2.02 (1.07-3.77) | ||||
CI indicates confidence interval; PTCL, peripheral T-cell lymphoma; HLA, human leukocyte antigen; BM, bone marrow; GVHD, graft-versus-host disease; and —, not applicable.
Those who received cord blood (n = 2) or BM + PBSC (n = 2) were excluded because of the small number of patients.
Seven patients using other GVHD prophylaxis were excluded.